Chemical Component Summary

Identifiers (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-{(E)-[(4-methylpiperazin-1-yl)imino]methyl}-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate
Formula C43 H58 N4 O12
Molecular Weight 822.94 g/mol
Type non-polymer
Isomeric SMILES CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C
InChI InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1

Chemical Details

Formal Charge 0
Atom Count 117
Chiral Atom Count 9
Chiral Atoms C12 C20 C21 C22 C23 C24 C25 C26 C27
Bond Count 121
Aromatic Bond Count 11

Drug Info: DrugBank

DrugBank ID DB01045   (Stereoisomeric match)
Name Rifampicin
Groups approved
Description A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
  • 3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin sv
  • RFP
  • Rifampicina
  • Rifampicinum
  • Rifampin
Salts Rifampicin sodium
Brand Names
  • Isonarif
  • Rifadin
  • Rifadin Cap 300mg
  • Rifadin IV
  • Rifamate
  • Rifampin
  • Rifater
  • Rofact 150mg
  • Rofact 300mg
  • Rifadine
  • Rifaldin
  • Rifoldin
  • Rimactan
  • Rimactane
  • Rofact
  • Tubocin
Affected Organism
  • Mycobacteria
  • Mycobacterium tuberculosis
  • Various gram-negative and gram-positive eubacteria
Indication For the treatment of Tuberculosis and Tuberculosis-related mycobacterial infections.
Pharmacology Rifampin is an antibiotic that inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. It is bactericidal and has a very broad spectrum of activity against most gram-positive and gram-negative organisms (including Pseudomonas aeruginosa) and specifically Mycobacterium tuberculosis. Because of rapid emergence of resistant bacteria, use is restricted to treatment of mycobacterial infections and a few other indications. Rifampin is well absorbed when taken orally and is distributed widely in body tissues and fluids, including the CSF. It is metabolized in the liver and eliminated in bile and, to a much lesser extent, in urine, but dose adjustments are unnecessary with renal insufficiency.
Mechanism of action Rifampin acts via the inhibition of DNA-dependent RNA polymerase, leading to a suppression of RNA synthesis and cell death.
Route of administration
  • intravenous
  • oral
  • oral; oral
  • Enzyme Inhibitors
  • Antitubercular Agents
  • Nucleic Acid Synthesis Inhibitors
  • Leprostatic Agents
  • Antibiotics, Antitubercular
  • Antibiotics
ATC-Code J04AB02
AHFS-Code 08:16.04
CAS number 13292-46-1
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID: 21059682